AKT1 and familial pancreatic carcinoma: The mTOR inhibitor, temsirolimus, induced tumour regressions in 4 of 17 (23%) freshly generated pancreatic cancer xenografts that were, in conjunction, characterised by genetic alterations, leading to an increased activation in the PI3K/Akt/mTOR pathway.